Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Somatostatinoma × palbociclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 96 Neoplasms 11 Neoplasm Metastasis 8 Sarcoma 6 Pancreatic Neoplasms 6 Ovarian Neoplasms 6 Melanoma 5 Colorectal Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Squamous Cell Carcinoma of Head and Neck 4 Prostatic Neoplasms 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Lung Neoplasms 4 Leukemia, Myeloid, Acute 4 Multiple Myeloma 3 Liposarcoma 3 Glioblastoma 3 Endometrial Neoplasms 3 Colonic Neoplasms 3 Breast Diseases 3 Brain Neoplasms 3 Triple Negative Breast Neoplasms 2 Recurrence 2 Neoplasm, Residual 2 Lymphoma, Non-Hodgkin 2 Inflammation 2 Head and Neck Neoplasms 2 Estrogen Receptor-positive Breast Cancer 2 Esophageal Squamous Cell Carcinoma 2 Chordoma 2

Interventions

Temozolomide 3 Leucovorin 3 Fluorouracil 3 Capecitabine 3 pentetreotide 2 Bevacizumab 2 veliparib 1 vatalanib 1 regorafenib 1 palbociclib 1 lutetium Lu 177 dotatate 1 irinotecan sucrosofate 1 gallium Ga 68 dotatate 1 dehydroftorafur 1 Thalidomide 1 Sunitinib 1 Panobinostat 1 Oxaliplatin 1 Octreotide 1 Magnetic Resonance Spectroscopy 1 Irinotecan 1 High-Energy Shock Waves 1 Everolimus 1 Doxorubicin 1 Bortezomib 1 Blood Specimen Collection 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02806648 2018-01-23

PALBONET

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡